BRIEF-Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer Models

Reuters

Feb 17

BRIEF-<a href="https://laohu8.com/S/TELO">Telomir Pharmaceuticals</a> Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer Models

Feb 17 (Reuters) - Telomir Pharmaceuticals Inc TELO.O:

TELOMIR PHARMACEUTICALS INC - DEMONSTRATES BROAD TUMOR CELL MORTALITY IN HUMAN TRIPLE-NEGATIVE BREAST CANCER MODELS
TELOMIR PHARMACEUTICALS INC - IRON-RESCUE EXPERIMENTS CONFIRM TUMOR CELL MORTALITY IS MECHANISTICALLY DRIVEN, NOT NONSPECIFIC CYTOTOXICITY
TELOMIR PHARMACEUTICALS INC - ANTICIPATES IND APPLICATION SUBMISSION IN Q1 2026 - SEC FILING

Source text: [ID:n0001493152-26-006937]

Further company coverage: TELO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612845749"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612845749\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612845749?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-17 21:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612845749","market":"fut","top_or_hot":-1,"title":"BRIEF-Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer Models","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/TELO\">Telomir Pharmaceuticals</a> Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer Models</title></head><body><p><span>Feb 17 (Reuters)</span><span> - </span>Telomir Pharmaceuticals Inc <span>TELO.O</span>:</p><ul><li><p>TELOMIR PHARMACEUTICALS INC - DEMONSTRATES BROAD TUMOR CELL MORTALITY IN HUMAN TRIPLE-NEGATIVE BREAST CANCER MODELS</p></li><li><p>TELOMIR PHARMACEUTICALS INC - IRON-RESCUE EXPERIMENTS CONFIRM TUMOR CELL MORTALITY IS MECHANISTICALLY DRIVEN, NOT NONSPECIFIC CYTOTOXICITY</p></li><li><p>TELOMIR PHARMACEUTICALS INC - ANTICIPATES IND APPLICATION SUBMISSION IN Q1 2026 - SEC FILING</p></li></ul><p>Source text: [ID:n0001493152-26-006937]</p><p>Further company coverage: <span>TELO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer Models</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer Models\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-17 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/TELO\">Telomir Pharmaceuticals</a> Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer Models</title></head><body><p><span>Feb 17 (Reuters)</span><span> - </span>Telomir Pharmaceuticals Inc <span>TELO.O</span>:</p><ul><li><p>TELOMIR PHARMACEUTICALS INC - DEMONSTRATES BROAD TUMOR CELL MORTALITY IN HUMAN TRIPLE-NEGATIVE BREAST CANCER MODELS</p></li><li><p>TELOMIR PHARMACEUTICALS INC - IRON-RESCUE EXPERIMENTS CONFIRM TUMOR CELL MORTALITY IS MECHANISTICALLY DRIVEN, NOT NONSPECIFIC CYTOTOXICITY</p></li><li><p>TELOMIR PHARMACEUTICALS INC - ANTICIPATES IND APPLICATION SUBMISSION IN Q1 2026 - SEC FILING</p></li></ul><p>Source text: [ID:n0001493152-26-006937]</p><p>Further company coverage: <span>TELO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD0CC:1","article_id":"2612845749","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612845749","pubTimestamp":1771335535,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer ModelsFeb 17 (Reuters) - Telomir Pharmaceuticals Inc TELO.O:TELOMIR PHARMACEUTICALS INC - D","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TELO":"Telomir Pharmaceuticals"},"translate_title":"BRIEF-Telomir Pharmaceuticals在人类三阴性乳腺癌模型中证明了广泛的肿瘤细胞死亡率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TELO":0.9},"content_text":"BRIEF-Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer ModelsFeb 17 (Reuters) - Telomir Pharmaceuticals Inc TELO.O:TELOMIR PHARMACEUTICALS INC - DEMONSTRATES BROAD TUMOR CELL MORTALITY IN HUMAN TRIPLE-NEGATIVE BREAST CANCER MODELSTELOMIR PHARMACEUTICALS INC - IRON-RESCUE EXPERIMENTS CONFIRM TUMOR CELL MORTALITY IS MECHANISTICALLY DRIVEN, NOT NONSPECIFIC CYTOTOXICITYTELOMIR PHARMACEUTICALS INC - ANTICIPATES IND APPLICATION SUBMISSION IN Q1 2026 - SEC FILINGSource text: [ID:n0001493152-26-006937]Further company coverage: TELO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}